{"slideshow_credits": null, "snippet": "A judge\u2019s decision sets up a likely court battle to determine just how far the government can go to punish speech that is truthful.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"lastname": "HENNING", "rank": 1, "firstname": "Peter", "role": "reported", "organization": "", "middlename": "J."}], "original": "By PETER J. HENNING"}, "web_url": "http://www.nytimes.com/2015/08/11/business/dealbook/fdas-off-label-drug-policy-leads-to-free-speech-fight.html", "lead_paragraph": "A judge\u2019s decision sets up a likely court battle to determine just how far the government can go to punish speech that is truthful.", "headline": {"main": "F.D.A.\u2019s \u2018Off-Label\u2019 Drug Policy Leads to Free-Speech Fight", "content_kicker": "White Collar Watch", "kicker": "White Collar Watch"}, "_id": "55c8ec0738f0d87d6b06f1b4", "word_count": "1152", "multimedia": [], "pub_date": "2015-08-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Engelmayer, Paul A", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Freedom of Speech and Expression", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "Amarin Corp PLC", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Suits and Litigation (Civil)", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}